Advanced searches left 3/3

REPEAT - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism Levels

In phase I/II trials assessing engraftment, efficacy, and toxicity at a variety of transplant centers, a variety of transplant centers are currently evaluating engraftment, compatibility, and toxicity. To reduce the incidence of graft rejection by graft rejection, an additional program is currently available for patients with a high risk of graft rejection that uses pentostatin and oral cyclophosphamide pre-transplant to deplete recipient lymphocytes in the hopes of lowering the risk of graft rejection, and the engraft rejection rate has substantially increased. In the first 5 patients transplanted, our new haploidentical transplant strategy has had some promising early results. We examined which donor chimerism level is required to reverse SCD among 67 patients under HLA-matched sibling or haploidentical PBSC transplants at the NIH. Three of the patients' donor myeloid chimerism levels were decreasing, and when the DMC level reached below 20%, the three patients' SCD was restored. Due to major differences in donor and recipient red blood cell survival, our mathematical model showed that only 20% DMC is required. After transplant, all three patients now have SCD with DMC levels of 100 percent at 1, 2, 2. 5, and 3. 5 years post-transplant. In patients with an HLA-matched sibling donor from the same donor and patients with decreased DMC and return of SCD in patients with increased myelosupression and CD34-selected PBSCs, we recommend repeat PBSC transplants using increased myelosupression and CD34-selected PBSCs in patients with a haploidentical donor and unmanipulated PBSCs using increased myelosupression and CD34-selected PBSCs.

Source link: https://clinicaltrials.gov/ct2/show/NCT04008368


Intraoperative Surgeon Administered Transversus Abdominis Plan (TAP) Block With Liposomal Bupivacaine and Post-operative Pain Control After Repeat Cesarean Delivery

"Infiltration of the skin and fascia with liposomal bupivacaine after cesarean did not have an effect, and this can be explained by the way that the pain fibers penetrate the TAP, making them amenable to a TAP block, while a superficial infiltration is ineffective. " The aim of this study is to determine if intraoperative surgeon administered TAP block reduces pain and use of oral and parenteral pain medications after repeat cesarean delivery. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05393908


Single Ascending Dose and Repeat Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, by Intravenous Infusion, or by Inhalation in Healthy Adult Subjects

"Blood samples for PK testing will be collected before and after each study drug testing. Before and up to 14 days after the second drug administration in Part 2, as well as before the first and up to 14 days after the second drug administration in Part 2's first and up to 14 days after the second drug administration in Part 2. Following the SC drug testing, three participants of Cohort 5 of Part 1 only will have a CSF sample for PK assessmen tonce after the SC drug administration. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05366283

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions